EF Hutton analyst Michael King reiterated a Buy rating on Sonnet BioTherapeutics Holdings (SONN – Research Report) today and set a price target of $6.70. The company’s shares opened today at $0.71.
King covers the Healthcare sector, focusing on stocks such as Coeptis Therapeutics Holdings, Biomea Fusion, and Sonnet BioTherapeutics Holdings. According to TipRanks, King has an average return of 4.5% and a 42.05% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sonnet BioTherapeutics Holdings with a $10.35 average price target.
See the top stocks recommended by analysts >>
SONN market cap is currently $14.56M and has a P/E ratio of -0.16.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SONN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sonnet BioTherapeutics (NASDAQ:SONN) is a clinical-stage biotechnology company that is focused on the development of drugs for the treatment of cancer.
Read More on SONN:
